Senores Pharmaceuticals Limited has filed a comprehensive regulatory disclosure under SEBI SAST regulations following the successful allotment of 11,70,000 convertible warrants worth ₹95.00 crore. The disclosure was submitted by promoter Swapnil Jatin Shah on behalf of all promoter and promoter group entities on April 01, 2026.

Warrant Allotment Structure

The company completed the allotment of warrants at an exercise price of ₹812.00 per warrant, aggregating to ₹95,00,40,000. The subscription amount received was ₹203.00 per warrant, representing 25% of the issue price and totaling ₹23,75,10,000. The remaining ₹609.00 per warrant will be payable upon conversion within 18 months.

SAST Regulatory Compliance

The disclosure filed under Regulation 29(2) of SEBI SAST Regulations provides detailed shareholding information for all promoter and promoter group entities. The warrants were allotted through preferential issue on March 28, 2026, with the regulatory filing submitted to both BSE (Scrip Code: 544319) and NSE (Symbol: SENORES).

Detailed Investor Allocation

The warrants were distributed among five promoter and promoter group entities, with Renosen Pharmaceuticals Private Limited receiving the largest allocation. The comprehensive allocation details show the strategic distribution among key stakeholders.

Comprehensive Shareholding Impact

The SAST disclosure reveals the complete promoter and promoter group shareholding structure, including entities like Remus Pharmaceuticals Limited, Aviraj Overseas LLC, and Espee Therapeutics LLP. The total promoter and promoter group holding stands at 2,11,00,357 shares representing 45.82% of the current share capital.

Capital Structure and Compliance

The allotment maintains compliance with all regulatory requirements under SEBI LODR and ICDR regulations. The warrants carry conversion rights to equity shares with a face value of ₹10.00 each and are subject to prescribed lock-in restrictions. The disclosure confirms that no shares are under encumbrance and no voting rights exist other than through equity shareholding.

The formal documentation was digitally signed by Swapnil Jatin Shah as the designated promoter representative, ensuring complete regulatory compliance and transparency in the preferential allotment process.

Senores Pharmaceuticals Limited has announced significant changes in its senior management personnel, with the appointment of a new Chief Technology Officer and the resignation of its President – Research and Development, both effective March 17, 2026.

Board Approves New CTO Appointment

The company's Board of Directors, through a circular resolution passed on March 17, 2026, approved the appointment and categorization of Mr. Jatin Gajjar as Chief Technology Officer and Senior Management Personnel. This decision was made based on the recommendation of the Nomination and Remuneration Committee, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Personnel Changes

New CTO's Professional Background

Mr. Jatin Gajjar brings over three decades of leadership experience in pharmaceutical technology, manufacturing operations, and product development to his new role. His expertise encompasses:

• Complex formulations and regulatory compliance
• Process optimization and novel drug delivery technologies
• Strategic leadership across R&D, manufacturing, and regulatory affairs
• Regulatory approvals and commercialization across key markets

Prior to joining Senores Pharmaceuticals, Mr. Gajjar served as President at QuoSolve Pharmaceutical Consultants and held leadership roles at several global pharmaceutical organizations including Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma, and Aventis Pharma.

Educational Qualifications

Mr. Gajjar holds comprehensive academic credentials in the pharmaceutical field:

• Bachelor's degree in Pharmacy from L.M. College of Pharmacy, Gujarat University
• Master's degree in Pharmacy from L.M. College of Pharmacy, Gujarat University
• Diploma in Marketing and Sales Management from RPICM, Bharatiya Vidya Bhavan

R&D Head Departure

Concurrently, Mr. Manohar Lalge, who served as President – Research and Development, tendered his resignation effective from the close of business hours on March 17, 2026. Upon his resignation, he ceased to be Senior Management Personnel of the company. The resignation letter, dated January 19, 2026, was formally accepted by the company's HR department.

Regulatory Compliance

The company has fulfilled all regulatory requirements by filing the necessary disclosures with both BSE Limited and the National Stock Exchange of India Limited. The information has also been uploaded on the company's website at www.senorespharma.com , ensuring complete transparency with stakeholders and regulatory authorities.